Search Results
Your search for The A,The A matches 32372 pages
Showing 12551 - 12600Cancer No Longer Scares Me
Cancer was a disease I feared until 3 years ago, when I was diagnosed with gastric cancer. After receiving the diagnosis, I knew I didn’t have any time to indulge in fear; I had to take action if I was going to survive. In hindsight, symptoms of the cancer, including some fatigue and indigestion,...
Everolimus/Octreotide Shows Antitumor Activity in Recurrent Meningioma
According to the results from the small phase II CEVOREM trial, a targeted combination of the mTOR inhibitor everolimus and the somatostatin agonist octreotide showed antitumor activity in patients with recurrent meningioma not amenable to any type of surgery or radiotherapy. These findings were...
Pathologic Fracture and Prognosis in Adult and Pediatric Patients With High-Grade Osteosarcoma
In a study reported in the Journal of Clinical Oncology, Kelley et al found that pathologic fracture was associated with poorer overall survival among adult—but not pediatric—patients with primary central high-grade osteosarcoma of the extremities. Study Details The study involved retrospective...
New NCCN Pediatric Cancer Guidelines for B-Cell Lymphomas
The National Comprehensive Cancer Network® (NCCN®) has published new guidelines for treating children, adolescents, and young adults with pediatric aggressive mature B-cell lymphomas, including Burkitt lymphoma and diffuse large B-cell lymphoma. NCCN published the first pediatric NCCN Clinical...
2020 GI Cancers Symposium: Higher Concentration of Fusobacterium nucleatum Found in Colorectal Tumors in Patients Younger Than 45
A bacterium typically linked to periodontal disease, Fusobacterium nucleatum, could play an important role in the rising incidence of colorectal cancer in people younger than age 45. Another type of bacteria, Moraxella osloensis, has been found in colorectal cancer tumors at a nearly fourfold...
Radiation Oncologist Felix Y. Feng, MD, Strives for Balance Between Work and Family Life
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Felix Y. Feng, MD, Professor of Radiation Oncology, Urology, and Medicine; George and Judy Marcus Distinguished Professor; Vice Chair of Translational Research in the Department of Radiation...
CancerCare to Provide Support for Patients With Cancer Impacted by the California Wildfires
As many California residents continue to deal with the aftermath of past wildfires and the advent of new ones, CancerCare is now offering a patient assistance program for both emotional and financial support to patients with cancer affected by the California fires. As a leading national nonprofit...
Steven N. Kalkanis, MD, Selected to Lead Henry Ford Medical Group
Following a national search, Henry Ford Health System has selected its own Steven N. Kalkanis, MD, as Chief Executive Officer of the Henry Ford Medical Group. He succeeds William A. Conway, MD, who is stepping down after more than 4 decades with the health system. Dr. Kalkanis will provide...
Ten Oncology Practices in Underserved Communities Receive Funding to Participate in Quality Improvement Programs
Ten oncology practices from rural and urban centers in the United States that primarily treat underserved populations have received grant funding to participate in ASCO’s Quality Oncology Practice Initiative (QOPI®) and Quality Training Program. The grants are supported by the Stavros Niarchos...
Optimizing Metabolic Discoveries
Obesity is a leading cause of cancer, and researchers are working to learn more about the biology behind the body’s metabolism and the promotion of cancer growth. “While we know that physical activity and a balanced diet are generally healthy, we don’t yet have the data to make personalized...
Start the New Year Right: Stock Your Practice With Trusted Patient Information Resources From ASCO
ASCO Answers’ award-winning guides, fact sheets, and booklets cover a broad range of important and popular topics in cancer care. ASCO Answers materials provide direct and easy-to-understand information on cancer types, diagnosis, treatment, side effects, and coping with the disease, making them...
Motivating Yourself for Exercise Goals in the New Year
The day after Christmas, I walked into the exercise studio and spent the next hour jogging, rowing, and doing exactly what that morning’s coach instructed the 20 or so participants of the class to do next. The hour passed quickly, and I had little or no time to think about anything other than the...
ASCO Releases Major Update to Payment Reform Model
ASCO released a major update to its Patient-Centered Oncology Payment (PCOP) model, an alternative payment model designed to support transformation in cancer care delivery and reimbursement, while ensuring that patients with cancer have access to high-quality, high-value care. PCOP addresses an...
ASCO Announces Newly Elected Leadership
ASCO has elected Everett E. Vokes, MD, FASCO, a long-time member and volunteer, to serve as its President for the term beginning in June 2021. Dr. Vokes will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2020. Six members were also elected to open positions on...
FDA’s Pilot Project Patient Voice Website and Workshop With ASCO
Project Patient Voice (PPV) is a program that will gather and make available online, patient-reported outcomes from cancer clinical trials. Launched by the U.S. Food and Drug Administration (FDA)’s Oncology Center of Excellence (OCE), it is the first program of its kind to communicate...
Value-Based and Patient-Centered Cancer Care: Looking at Closing Gaps in Perspectives of Value
Value-based care in oncology—a concept that emphasizes quality over quantity—has evolved over the past 2 decades to become a guiding principle of both public and private payers. The concept was part of the Medicare Improvements for Patients and Providers Act (MIPPA) of 2008; informed elements of...
Two New Grants to Support Transformative Cancer Research
Two grants for research that could transform cancer therapies have been funded through an innovative partnership between the American Association for Cancer Research (AACR) and MPM Capital through its management of the UBS Oncology Impact Fund. This unique grant program allows investigators to...
Stephanie Lee, MD, MPH, Begins Term as ASH President
Stephanie Lee, MD, MPH, an expert in graft-vs-host disease as well as blood and bone marrow diseases, will serve as President of the American Society of Hematology (ASH) for a 1-long term through December 2020. Dr. Lee is a member and Associate Director of the Clinical Research Division at Fred...
American Cancer Society Welcomes Three New Members to the Board of Directors
The American Cancer Society (ACS) has announced three new members to the Board of Directors, effective January 1, 2020. Joining the ACS board are Katie Eccles, Patrick Geraghty, and Oyebode Taiwo, MD, MPH. The ACS Board of Directors consists of 21 members, which include 5 officers (elected for a ...
Price Transparency and Variation for Prostate Cancer Radiation Therapy
In a study reported in JAMA Oncology, Trevor Royce, MS, MD, MPH, and colleagues found that publicly available information on pricing for radiation treatment for prostate cancer was complex and inconsistent, and that pricing varied widely among National Cancer Institute (NCI)-designated cancer...
2020 GI Cancers Symposium: Young Adults With Colorectal Cancer Living in Areas of Low Income, Education Likely to Have Worse Survival Outcomes
A retrospective analysis of 26,768 young adults with colorectal cancer aged 40 and under found that those who live in areas with lower income (a median income of less than $38,000) and less education (under 79% high school graduation rate), as well as those who live in urban areas, had worse...
2020 GI Cancers Symposium: Patient-Reported Outcomes From IMbrave150, BEACON CRC
Patient-reported outcomes from two large studies show that quality of life is maintained longer with newer drug combinations compared with standard-of-care treatments in patients with unresectable hepatocellular carcinoma and BRAF V600E–mutant metastatic colorectal cancer. The results, from...
2020 GI Cancers Symposium: Detecting GI Tumors Using a Cell-Free DNA Test
A blood-based screening test using cell-free DNA to identify methylation signals of hard-to-detect gastrointestinal (GI) cancers could potentially help detect disease at earlier stages. This research will be presented by Brian M. Wolpin, MD, MPH, and colleagues at the 2020 Gastrointestinal Cancers...
Expert Point of View: Hope S. Rugo, MD, FASCO, and Laura J. Esserman, MD, MBA, FASCO
Hope S. Rugo, MD, FASCO, Professor of Medicine, Director of Breast Oncology and Clinical Trials at the University of California, San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center, said the residual cancer burden index is being increasingly used in medical oncology. “The...
Residual Cancer Burden Is Prognostic of Outcomes Across Breast Cancer Subtypes
Residual cancer burden after neoadjuvant chemotherapy can accurately predict disease recurrence and survival across all breast cancer subtypes, according to the findings from a meta-analysis presented at the 2019 San Antonio Breast Cancer Symposium by W. Fraser Symmans, MD, Professor and Director...
Expert Point of View: Debra Patt, MD, MPH, MBA
Debra Patt, MD, MPH, MBA, Executive Vice President of Policy and Strategy for Texas Oncology and Clinical Professor at Dell Medical School at the University of Texas at Austin, commented that the 10-year results of NSABP B-42 show “a substantial improvement” in disease-free survival, with an...
Extended Letrozole Boosts Disease-Free Survival in 10-Year Update of NSABP B-42 Trial
“In the 10-year analysis of the NSABP B-42 trial, the effect of extended treatment with 5 years of letrozole on disease-free survival persisted and reached statistical significance. There was no significant improvement in overall survival with letrozole, but letrozole continued to provide a...
Expert Point of View: Michael Jain, MD, PhD
Michael Jain, MD, PhD, of the Moffitt Cancer Center, Tampa, Florida, commented on both studies with the combination of brentuximab vedotin/nivolumab. “For older patients, ABVD [doxorubicin, bleomycin, vinblastine, dacarbazine] is not easy to tolerate, and it would be good to find an easier...
Brentuximab Vedotin Plus Nivolumab in Hodgkin Lymphoma
The combination of brentuximab vedotin and nivolumab is making headway as first-line therapy for older adults with Hodgkin lymphoma and as salvage therapy for adults with relapsed or refractory classic Hodgkin lymphoma, according to separate studies presented at the 2019 Annual Meeting &...
Does Proton Pump Inhibitor Use Affect Cognition in Breast Cancer Survivors?
Proton pump inhibitors, which are sometimes recommended to ease stomach problems during cancer treatment, may have an unintended side effect: impairment of breast cancer survivors' memory and concentration. These findings were published by Madison et al in the Journal of Cancer Survivorship....
Using T-Cell Fraction to Predict Melanoma Recurrence
In a paper published by Pruessmann et al in Nature Cancer, investigators presented a new, quantitative technique that leverages DNA sequencing to make more sophisticated and accurate predictions about which primary melanomas are likely to recur and spread. "As recently as 10 years ago, the outlook...
Immune-Related Adverse Events and Recurrence-Free Survival With Adjuvant Immunotherapy vs Placebo in Stage III Melanoma
In an analysis of the EORTC 1325/KEYNOTE-054 trial of adjuvant pembrolizumab vs placebo in stage III melanoma reported in JAMA Oncology, Alexander M.M. Eggermont, MD, PhD, and colleagues found that patients treated with pembrolizumab who experienced immune-related adverse events had improved...
Impact of the NCI Cell-Line Database: A Testament to Patient Altruism
In an homage to the gracious patients who provided biospecimens and to the dedicated researchers who have tended and studied the derived cell lines, James L. Mulshine, MD, of the Center for Healthy Aging, Department of Internal Medicine, Rush University, and colleagues have described the impact of...
Mixed Results With Weekly Nab-paclitaxel, Denosumab in Primary Breast Cancer
A weekly schedule of nab-paclitaxel as part of neoadjuvant chemotherapy significantly improved pathologic complete response compared with nab-paclitaxel given 2 weeks out of every 3 weeks (2/3) in patients with primary breast cancer, with a greater magnitude of benefit in patients with...
Cancer Incidence in World Trade Center Responders to the September 11 Attacks
A study published by Shapiro et al in JNCI Cancer Spectrum showed that responders to the World Trade Center site after the attacks on September 11, 2001, have statistically significant elevations in cancer incidence for all cancer sites combined, and for prostate and thyroid cancer and leukemia....
Three Studies Examine Relationship Between B-Cell Enrichment and Response to Immunotherapy
The likelihood of a patient responding to immune checkpoint blockade may depend on B cells in the tumor, located within specialized immune-cell clusters known as tertiary lymphoid structures, according to three studies all recently published in Nature. The studies showed that enrichment of B cells...
Relapse and Outcomes in Men Receiving Adjuvant Bleomycin/Etoposide/Cisplatin for Clinical Stage I Nonseminoma
In a study reported in the Journal of Clinical Oncology, Fischer et al found different patterns of relapse and associated outcomes among men with relapse after treatment with adjuvant bleomycin/etoposide/cisplatin for clinical stage I nonseminoma. The study included data on 51 patients from 18...
Entrectinib in Advanced ROS1 Fusion–Positive NSCLC
As reported in The Lancet Oncology by Alexander Drilon, MD, and colleagues, an integrated analysis of three phase I/II trials has shown high activity of the TRK and ROS1 inhibitor entrectinib in ROS1 fusion-positive non–small cell lung cancer (NSCLC). This analysis supported the August 2019 U.S....
Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes
We’ll start off this week by discussing results from the MEDALIST trial of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes. Then, we’ll move to a study that’s been covered a lot in the news: does the use of powder in the genital area increase a woman’s chance of ovarian...
Society for Integrative Oncology’s 16th International Conference
The Society for Integrative Oncology (SIO) hosted its 16th International Conference in New York City, October 19-21, 2019, in partnership with Memorial Sloan Kettering Cancer Center (MSK). The conference theme, “Advancing the Science and Art of Integrative Oncology,” focused on deepening the...
FDA Pipeline: Priority Reviews in Ovarian Cancer, Prostate Cancer, and NSCLC
This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to treatments for ovarian, prostate, and lung cancer; granted Orphan Drug designation to therapies for chemotherapy-induced thrombocytopenia and multiple myeloma; and granted Breakthrough Device designation to platforms...
Treatment Resistance and Novel Therapies in FGFR-Mutated Cholangiocarcinoma
A new study has shown how resistance to fibroblast growth factor receptor (FGFR) inhibitor treatment develops in patients with cholangiocarcinoma and suggests that adding another therapy at the time of disease progression might resensitize tumor cells to initial therapy. These findings were...
External-Beam Accelerated Partial-Breast Irradiation vs Whole-Breast Irradiation After Breast-Conserving Surgery in DCIS or Node-Negative Breast Cancer
As reported in The Lancet by Timothy J. Whelan, BM, BCh, and colleagues, the phase III noninferiority RAPID trial has shown that external-beam accelerated partial-breast irradiation is noninferior to whole-breast irradiation in reducing risk of local recurrence after breast-conserving surgery in...
Conditioning Intensity for Allogeneic Transplantation in Patients With AML
In a study reported in the Journal of Clinical Oncology, Hourigan et al found that reduced-intensity conditioning for allogeneic hematopoietic cell transplantation was associated with poorer outcomes vs myeloablative conditioning in patients with acute myeloid leukemia (AML) who had genomic...
Comparing Options for Ovarian Tissue Cryopreservation to Preserve Fertility in Pediatric Patients With Cancer
With the pediatric cancer survival rate exceeding 80%, “we can reasonably suspect that most of these children will survive more than 5 years from their diagnosis and then go on to puberty,” when they may have to deal with the consequences of cancer treatment, according to Rebecca Flyckt, MD,...
Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous NSCLC
In a Japanese phase III trial reported in the Journal of Clinical Oncology, Seto et al found that the addition of maintenance pemetrexed to bevacizumab did not significantly improve overall survival in patients with previously untreated, advanced nonsquamous non–small cell lung cancer (NSCLC)...
Genomic Aberrations and Pancreatic Cancer Subtypes
Researchers have discovered detailed new genetic information about the subtypes of pancreatic cancer. A better understanding of the disease groups may lead to new treatment options and improved clinical outcomes for this lethal disease, Chan-Seng-Yue et al reported in Nature Genetics. The study...
Are Women in Europe or Asia More Likely to Have Breast-Conserving Therapy Than Those in the United States?
Neoadjuvant systemic therapy can shrink tumors in patients with breast cancer and, in some cases, allow patients to receive breast-conserving therapy who would otherwise require mastectomy. However, in the United States, about 55% of patients who become eligible for breast-conserving therapy after...
Expert Point of View: Howard J. Weinstein, MD
Commenting on the blinatumomab study, Howard J. Weinstein, MD, Chief of Pediatric Hematology-Oncology at Massachusetts General Hospital for Children and Harvard Medical School in Boston, said: “These are very promising results for children, adolescents, and young adults who have had a first...
Selected Abstracts on Novel Therapies for Chronic Myeloid Leukemia
To complement The ASCO Post’s comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens for chronic myeloid leukemia (CML). For full details of...
